| Source: |
| Type: oncogene |
| The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells. -C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A Inhibitors (downregulate): Curcumin Resveratrol: downregulate c-Myc expression. Epigallocatechin Gallate (EGCG) Quercetin Berberine: decrease c-Myc expression and repress its transcriptional activity. |
| Bladder Cancer |
| 1214- | VitK2, | Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | J82 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:32 Cells:% prod#:% Target#:35 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid